Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: An assessment using the FDA adverse event reporting system

Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: An assessment using the FDA adverse event reporting system

Methotrexate (MTX) is an essential anti-rheumatic drug used to treat rheumatoid arthritis (RA). Prevention or management of adverse reactions, including interstitial lung disease (ILD), hepatotoxicity, myelosuppression, and infection, remains fundamental for safe MTX therapy. Using the Food and Drug...

Full description

Bibliographic Details
Main Authors: Kenji Onda, Takeshi Honma, Koichi Masuyama
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Pharmacology
Subjects:
methotrexate
FAERS database
folic acid
TNFalpha inhibitor
interstitial lung disease
hepatotoxicity
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1030832/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1030832/full

Similar Items